stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
50.89
2.43
+5.01%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Operating cash flow
MBX Biosciences, Inc.'s operating cash flow for fiscal 2025 was −$79.9M, compared with −$54.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$82.7M. Operating cash flow has fallen for 3 consecutive fiscal years. MBX Biosciences, Inc. ranks 427th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$79.9M | — |
| FY2024 | −$54.7M | — |
| FY2023 | −$32.0M | — |
| FY2022 | −$23.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$22.6M | — |
| Mar 2026 | −$20.2M | — |
| Dec 2025 | −$18.3M | — |
| Sep 2025 | −$21.5M | — |
| 9 more quarters | Free account |
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.8M |
| MBX MBX Biosciences, Inc. | −$82.7M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.5M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$159.2M |
| PHVS Pharvaris N.V. compare | −$178.0M |
| XNCR Xencor, Inc. compare | −$205.8M |
| CLDX Celldex Therapeutics, Inc. compare | −$235.6M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item